Amicus Therapeutics (FOLD) IPO Trades Higher
More News related to FOLD
- Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
- Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
- Amicus Therapeutics (FOLD) Reports Smaller Than Expected Q1 Loss; Revs Light
- Amicus Therapeutics Announces First Quarter 2009 Financial Results
- Amicus (FOLD) Files $100M Mixed Securities Shelf
The IPO Amicus Therapeutics (Nasdaq: FOLD) is open for trading. The stock is trading at $16.34 after pricing at $15.00, the middle of the expected $14.00-16.00 range.
Morgan Stanley & Co. Incorporated and Merrill Lynch & Co. served as joint book-runners for the offering, with J.P. Morgan Securities Inc., Lazard Capital Markets LLC, and Pacific Growth Equities, LLC acting as co-managers.
Amicus Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.
Related Categories
IPOsStocks Mentioned
-0.96Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
